₹485.9
▼ -6.25 -1.27%
18 Jul 2026
NSE Listed · Healthcare
Dr. Agarwal's Health Care Limited (AGARWALEYE)
Volume: 1,621Avg Vol 1W: 42,657Avg Vol 1M: 54,99352W Range:₹401₹568
Key Ratios
Checked 9h agoMarket Cap₹15,404 Cr
Current Price₹485.9
Previous Close₹492.15
High / Low (52w)₹568 / ₹401
Volume1,621
Avg Vol (1W)42,657
Avg Vol (1M)54,993
Stock P/E116.52
Book Value₹63.89
Dividend Yield0%
ROE6.58%
ROA426.56%
Revenue (TTM)—
Revenue Growth28.44%
Profit Margin6.4%
Total Debt₹157 Cr
Shares Outstanding32 Cr
Face Value₹1
EPS (TTM)₹4.17
P/B7.61
Debt / Equity0.6
50 DMA₹473.06
200 DMA₹453.31
Day change-1.27%
Price Chart
₹485.9▼ 4.09% · 1Y
2025-11-242026-07-17
20-day avg volume: 57K shares
Pros
- Company is almost debt-free.
- Revenue grew 28% YoY.
Cons
- Stock trades at a high P/E of 117.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹403 Cr | ₹417 Cr | ₹431 Cr | ₹460 Cr | ₹487 Cr | ₹499 Cr | ₹530 Cr | ₹564 Cr |
| EBITDA | ₹54 Cr | ₹62 Cr | ₹69 Cr | ₹86 Cr | ₹78 Cr | ₹76 Cr | ₹86 Cr | ₹97 Cr |
| Net Profit | ₹12 Cr | ₹17 Cr | ₹22 Cr | ₹33 Cr | ₹30 Cr | ₹30 Cr | ₹34 Cr | ₹40 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Revenue | ₹544 Cr | ₹477 Cr | ₹714 Cr | ₹1,031 Cr | ₹1,376 Cr | ₹1,757 Cr |
| EBITDA | ₹40 Cr | ₹-7 Cr | ₹102 Cr | ₹156 Cr | ₹236 Cr | ₹272 Cr |
| Net Profit | ₹-21 Cr | ₹-55 Cr | ₹38 Cr | ₹94 Cr | ₹83 Cr | ₹83 Cr |
| EPS | -29.93 | -80.87 | 1.83 | 4 | 3.13 | 2.78 |
Balance Sheet
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Total Assets | ₹752 Cr | ₹787 Cr | ₹1,026 Cr | ₹1,825 Cr | ₹2,753 Cr | ₹3,672 Cr |
| Total Liabilities | ₹485 Cr | ₹588 Cr | ₹792 Cr | ₹1,166 Cr | ₹1,373 Cr | ₹1,745 Cr |
| Equity | ₹267 Cr | ₹199 Cr | ₹234 Cr | ₹659 Cr | ₹1,380 Cr | ₹1,927 Cr |
| Total Debt | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Operating | ₹120 Cr | ₹107 Cr | ₹180 Cr | ₹268 Cr | ₹378 Cr | ₹397 Cr |
| Investing | ₹-80 Cr | ₹-37 Cr | ₹-155 Cr | ₹-509 Cr | ₹-914 Cr | ₹-750 Cr |
| Financing | ₹-73 Cr | ₹-37 Cr | ₹35 Cr | ₹303 Cr | ₹553 Cr | ₹382 Cr |
| Free Cash Flow | ₹120 Cr | ₹107 Cr | ₹180 Cr | ₹267 Cr | ₹377 Cr | ₹385 Cr |
Shareholding
Promoter 32.34% Institutions 65.68% Public 1.98%
Efficiency & Working Capital
ROCE9.8%
Interest Coverage2.4
Dividend Payout—
Debtor Days26 d
Inventory Days17 d
Payable Days33 d
Cash Conversion Cycle11 d
Working Capital Days43 d
Shareholding Details
As of 2026-06-30
Promoter32.3%
FII58%
DII7.7%
Institutions65.7%
Public2%
Promoter Pledge0%
No. of Shareholders42,492
Shareholding Pattern
Quarterly — figures in %. Latest 10 quarters.
| Period | Sept 2024 | Jan 2025 | Jan 2025 | Feb 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 37.8% | 37.7% | 37.7% | 32.5% | 32.5% | 32.4% | 32.4% | 32.4% | 32.4% | 32.3% |
| FIIs | 0% | 0% | 0% | 57% | 60.6% | 59.3% | 58.1% | 58.1% | 57.9% | 58% |
| DIIs | 0% | 62.3% | 0% | 5.1% | 5.2% | 6.4% | 7.9% | 7.8% | 7.8% | 7.7% |
| Public | 62.2% | 0% | 62.3% | 5.5% | 1.7% | 1.9% | 1.5% | 1.8% | 1.9% | 2% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 29 | 43 | 43 | 2,17,289 | 68,696 | 63,021 | 48,168 | 46,554 | 43,538 | 42,492 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Hyperion Investments Pte. Ltd. | Public Shareholding | 23.1% | 7.32 Cr |
| Claymore Investments (mauritius) Pte. Ltd | Public Shareholding | 10.2% | 3.23 Cr |
| Arvon Investments Pte.ltd. | Public Shareholding | 9.9% | 3.13 Cr |
| Government Of Singapore | Public Shareholding | 6.4% | 2.01 Cr |
| Athiya Agarwal | Shareholding of Promoter and Promoter Group | 4.5% | 1.41 Cr |
| Amar Agarwal | Shareholding of Promoter and Promoter Group | 4.5% | 1.41 Cr |
| Ashar Agarwal | Shareholding of Promoter and Promoter Group | 4.5% | 1.41 Cr |
| Ashvin Agarwal | Shareholding of Promoter and Promoter Group | 4.5% | 1.41 Cr |
| Adil Agarwal | Shareholding of Promoter and Promoter Group | 4.4% | 1.40 Cr |
| Adil Agarwal, Anosh Agarwal, Ashvin Agarwal | Shareholding of Promoter and Promoter Group | 4.3% | 1.35 Cr |
| Anosh Agarwal | Shareholding of Promoter and Promoter Group | 4.2% | 1.34 Cr |
| Invesco India Flexi Cap Fund | Public Shareholding | 3% | 95,86,950 |
| Polar Capital Funds Plc - Healthcare Opportunities | Public Shareholding | 1.6% | 51,22,166 |
| Motilal Oswal S&p Bse Healthcare Etf | Public Shareholding | 1.5% | 46,47,114 |
| Dr. Agarwal's Eye Institute (p) Limited | Shareholding of Promoter and Promoter Group | 1.4% | 43,42,320 |
| Franklin Templeton Investment Funds - Franklin Ind | Public Shareholding | 1.1% | 36,07,733 |
| Monetary Authority Of Singapore | Public Shareholding | 1.1% | 35,05,183 |
| Axis Max Life Insurance Limited A/c - Ulif01311/02 | Public Shareholding | 1.1% | 33,73,046 |
| A Urmila | Shareholding of Promoter and Promoter Group | 0.2% | 7,43,785 |
| Anosh Agarwal Holding On Behalf Of Dr. Adil Agarwal Family Trust | Shareholding of Promoter and Promoter Group | 0% | 30 |
| Anosh Agarwal Holding On Behalf Of Dr. Ashar Agarwal Family Trust | Shareholding of Promoter and Promoter Group | 0% | 30 |
| Anosh Agarwal Holding On Behalf Of Dr. Ashvin Agarwal Family Trust | Shareholding of Promoter and Promoter Group | 0% | 30 |
| Anosh Agarwal Holding On Behalf Of Dr. Anosh Agarwal Family Trust | Shareholding of Promoter and Promoter Group | 0% | 30 |
| Anosh Agarwal Holding On Behalf Of Dr. Amar Agarwal Family Trust | Shareholding of Promoter and Promoter Group | 0% | 30 |
| Ace Associates | Shareholding of Promoter and Promoter Group | 0% | 0 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Athiya Agarwal | 0 | 0% | 2026-06-30 |
| Amar Agarwal | 0 | 0% | 2026-06-30 |
| Adil Agarwal | 0 | 0% | 2026-06-30 |
| Anosh Agarwal | 0 | 0% | 2026-06-30 |
| A Urmila | 0 | 0% | 2026-06-30 |
| Ashar Agarwal | 0 | 0% | 2026-06-30 |
| Ashvin Agarwal | 0 | 0% | 2026-06-30 |
| Farah Agarwal | 0 | 0% | 2026-06-30 |
| Rambha Seth | 0 | 0% | 2026-06-30 |
| Kaamna Kakkar | 0 | 0% | 2026-06-30 |
| Tejeshwar Seth | 0 | 0% | 2026-06-30 |
| Kamalesh Kumar Seth | 0 | 0% | 2026-06-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Amar Agarwal. | Chairman & Non Executive Dir. | 2025 |
| Adil Agarwal | ED / WTD / CEO / Promoter | 2025 |
| Anosh Agarwal | ED / WTD / CFO / Promoter | 2025 |
| ANKUR NAND THADANI | Non Executive Director / Nominee | 2025 |
| Ved Kalanoria | Non Executive Director / Nominee | 2025 |
| Ranjan Pai | Independent Non Exe. Director | 2025 |
| Nachiket Mor | Independent Non Exe. Director | 2025 |
| Archana Bhaskar | Independent Non Exe. Director | 2025 |
| V Balakrishnan | Independent Non Exe. Director | 2025 |
| Sanjay Anand | Independent Non Exe. Director | 2025 |
| A Thanikainathan | VP / Company Secretary / Compliance Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Eye care related sales and services | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| Within India | ₹1,035 Cr | 99.1% |
| Outside India | ₹9 Cr | 0.9% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹1 | 54 | 32 | 32 |
Substantial Acquisitions (SAST)
11 disclosure(s)
NULL03/03/2026 · 21,15,180
NULL13/02/2026 · 14,85,822
Gift31/12/2025 · 5,12,473
Gift31/12/2025 · 5,12,473
Inter-se Transfer04/12/2025 · 9,40,578
Inter-se Transfer28/06/2025 - 01/07/2025 · 98,68,878
Company Information
🌐 www.dragarwals.co.in ↗
📍 6th Floor Menon Eternity, 1st Main Road Auston Nagar, Chennai, Tamil Nadu, 600018
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search